Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk
Rhea-AI Filing Summary
Context Therapeutics Inc. reports that on July 29, 2026 it received a written notice from Nasdaq stating its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule, because the closing bid price was below $1.00 per share for 30 consecutive business days.
The company has an initial 180-day grace period, until January 25, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days, with Nasdaq able to extend that 10-day window. If needed, the company may seek a second 180-day compliance period, subject to meeting other Nasdaq Capital Market listing standards and notifying Nasdaq of its intent to cure the deficiency.
If compliance is not restored within the allowed periods, Nasdaq may move to delist the shares, a decision the company could appeal to a Nasdaq Hearings Panel. Context Therapeutics states it will monitor its bid price and evaluate options, while cautioning there is no assurance it will regain compliance.
Positive
- None.
Negative
- Nasdaq notified the company that its stock fell below the $1.00 minimum bid for 30 consecutive business days, starting a 180-day cure period and creating a potential delisting risk if bid-price compliance is not regained.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance period: 30 consecutive business days
Initial compliance period: 180 calendar days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Required closing bid under Nasdaq Listing Rule 5550(a)(2) to maintain listing
Non-compliance period
30 consecutive business days
Length of time the bid price was below $1.00 that triggered the Nasdaq notice
Initial compliance period
180 calendar days
Grace period ending January 25, 2027 to regain minimum bid-price compliance
Compliance trading window
10 consecutive business days
Minimum span the bid must close at or above $1.00 to regain compliance
Potential second compliance period
180 calendar days
Additional cure period available if other Nasdaq Capital Market listing standards are met
Key Terms
Nasdaq Listing Rule 5550(a)(2), Minimum Bid Price Rule, Nasdaq Capital Market, Second Compliance Period, +1 more
5 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"not in compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule"
Minimum Bid Price Rule regulatory
"the company was not in compliance with the Minimum Bid Price Rule"
A minimum bid price rule is a stock market requirement that a listed company's share must trade above a set minimum price over a specified period to remain listed on an exchange. It matters to investors because falling below that threshold can trigger warnings, potential delisting, and reduced liquidity—similar to a student needing a passing grade to stay enrolled—making the shares harder to buy, sell, or value accurately.
Nasdaq Capital Market regulatory
"meet all other applicable standards for initial listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Second Compliance Period regulatory
"the Company may be eligible for an additional 180-day period, the Second Compliance Period"
Nasdaq Hearings Panel regulatory
"the Company may appeal the Staff’s delisting determination to a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq notice did Context Therapeutics (CNTX) receive on July 29, 2026?
Nasdaq notified Context Therapeutics that its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid stayed below $1.00 per share for 30 consecutive business days, triggering a formal minimum bid-price deficiency process.
How long does Context Therapeutics (CNTX) have to regain Nasdaq bid-price compliance?
Context Therapeutics has an initial 180 calendar days, until January 25, 2027, to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days within this period, subject to Nasdaq discretion.
What is the potential Second Compliance Period for Context Therapeutics (CNTX)?
If CNTX does not regain compliance by January 25, 2027, it may qualify for a Second Compliance Period of up to 180 additional calendar days, provided it meets market value of publicly held shares and other initial Nasdaq Capital Market standards and notifies Nasdaq of its cure plan.
What happens if Context Therapeutics (CNTX) still fails to meet Nasdaq’s bid-price rule?
If compliance is not regained within the allowed period or periods, Nasdaq staff may move to delist the company’s common stock. Context Therapeutics would then receive written notice and could appeal the delisting determination to a Nasdaq Hearings Panel, though success is not assured.
How does Context Therapeutics (CNTX) plan to address the Nasdaq bid-price deficiency?
The company states it intends to actively monitor the closing bid price of its common stock and evaluate available options to resolve the deficiency. However, it cautions there is no assurance it will regain compliance, obtain a Second Compliance Period, or maintain Nasdaq listing requirements.